|
Comparison of the heart and liver iron deposition status in Major β Thalassemia patients treated with two iron chelation drugs of “Deferoxamine and Deferasiroxon” using MRI T2* technique
|
B. Moradveisi   , R. Taghizadeh Sarvestani , E. Ghaderi , F. Kompany |
|
|
| Keywords: Key words : beta-Thalassemia, Deferoxamine, Iron Overload, Magnetic Resonance Imaging |
|
|
Full-Text [PDF 291 kb]
(3729 Downloads)
| Abstract (HTML) (8760 Views)
|
Type of Study: Research |
Subject:
Hematology
Published: 2015/04/7
|
|
|
|
|
|
|
Full-Text: (5154 Views) |
References :
- Aydin B, Yaprak I, Akarsu D, Okten N, Ulgen M. Psychosocial aspects and psychiatric disorders in children with thalassemia major. Acta paediatr Jpn 1997; 39(3): 354-7.
- Hosseini Sh, Khani H, Khalilian A, Vahidshahi K. Psychological aspects in young adults with Beta- Thalassemia major, control group. Journal of Mazandaran University of Medical Sciences 2007; 17(59): 51-60. [Article in Farsi]
- Sobouti B. [Nelson Textbook of Pediatrics: Hematology Diseases]. 19th ed; 2011. p. 58.
- Porter JB. Practical management of iron overload. Br J Haematol 2001; 115(2): 239-52.
- Khalifa AS, Sheir S, el Magd LA, el Tayeb H, el Lamie O, Khalifa A, et al. The kidney in beta-thalassemia major. Acta Haematol 1985; 74(1): 60.
- Wood JC, Ghugre N. Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin 2008; 32(12): 85-96.
- Argyropoulou MI, Astrakas L. MRI evaluation of tissue iron burden in patients with beta-thalassaemia major. Pediatr Radiol 2007; 37(12): 1191-200.
- Au W, Lam W, Chu W, Tam S, Wong W, Liang R,et al. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica 2008; 93(1): 116-9.
- Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE. Nathan and Oski’s Hematology of Infancy and Childhood. 7th ed; 2009. p. 1051-68.
- Voskaridou E, Douskou M, Terpos E, Papassotiriou I,
Stamoulakatou A, Ourailidis A, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol 2004; 126(5): 736-42.
- Peng CT, Tsai CH, Wu KH. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin 2008; 32(12): 49-62.
- Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2006; 136(3): 501-8.
- Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010; 116(4): 537-43.
- Moradi G, Ghaderi E. Chronic disease program in Iran: Thalassemia control program. Chronic Diseases Journal 2013; 1(2): 98-106.
- Keikhaei B. Sequential Deferoxamine - Deferasirox in treatment of Major Thalassemia with Iron Overload. Iranian Journal of Pediatric Hematology and Oncology 2010; 1(1): 14-8.
- Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al. Deferasirox, deferipron and deferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011; 96(1): 41-7.
|
|
|
|
|
|
Sci J Iran Blood Transfus Organ 2015; 12(1): 55-62
|
|
|
|
|
|
Comparison of the heart and liver iron deposition status
in Major β Thalassemia patients treated with two iron
chelation drugs of “Deferoxamine and Deferasiroxon”
using MRI T2* technique
Moradveisi B.1, Taghizadeh Sarvestani R.1, Ghaderi E.2, Kompany F.3
1Kurdistan University of Medical Sciences, Sanandaj, Iran
2Kurdistan Research Center for Social Determinants of Health, Kurdistan University of Medical Sciences, Sanandaj, Iran
3Tehran University of Medical Sciences, Tehran, Iran
Abstract
Background and Objectives
Blood transfusion causes many complications in major β thalassemia patients. In this study, the heart and liver iron deposition stata measured by MRI T2* technique in patients that are being treated by two iron chelation drugs of “deferoxamine and deferasirox” are compared.
Materials and Methods
In an Experimental Study, 52 β-thalassemia patients treated with deferoxamine or deferasirox at least two years before the study were evaluated. In all patients, the liver and heart MRI T2* was taken and then the heart and liver iron deposition status was compared. The collected data were analyzed by SPSS software and statistical methods: Mann–Whitney U test and Spearman's rank correlation coefficient.
Results
23 female and 29 male were evaluated. The mean age in deferoxamine and deferasirox group were 17.7 (± 7.1) and 16.5 (± 7.3) years, respectively (p= 0.593). Mean of ferritin level in deferoxamine group was 2857.57 (± 2037.63) and in deferasirox group was 2067.42 (± 1789.18) ng/mL (p= 0.207). Mean of received packed cell was 150-180 cc/kg. The mean of liver MRI T2* relaxation time in deferoxamine group was 3.29 (± 2.07) msec and in deferasirox group was 3.37 (± 10.39) msec (p= 0.359). The mean of cardiac MRI T2* relaxation time in deferoxamine and deferasirox groups were 25.67 (± 10.73) and 29.1 (± 10.27) msec, respectively (p= 0.470).
Conclusions
Deferasirox is relatively more effective than deferoxamine in reducing iron content of the liver and heart. Moreover, deferasirox is more effective in reducing cardiac iron content relative to liver iron content.
Key words: beta-Thalassemia, Deferoxamine, Iron Overload, Magnetic Resonance Imaging
Received: 8 Mar 2014
Accepted: 12 Oct 2014
Correspondence: Taghizadeh Sarvestani R. Student of Pediatric Medicine of Kurdistan University of Medical Sciences.
P.O.Box: 66179-67617, Sanandaj, Iran. Tel: (+98871) 3282002; Fax: (+98871) 3285890
E-mail: rt_sarvestani@yahoo.com
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Moradveisi B, Taghizadeh Sarvestani R, Ghaderi E, Kompany F. Comparison of the heart and liver iron deposition status in Major β Thalassemia patients treated with two iron chelation drugs of “Deferoxamine and Deferasiroxon” using MRI T2* technique. Sci J Iran Blood Transfus Organ 2015; 12 (1) :55-62 URL: http://bloodjournal.ir/article-1-844-en.html
|
.jpg)
.png)
